These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29324464)

  • 1. Sacubitril/Valsartan-Associated Small Bowel Ileus.
    Hanefeld-Fox L; Jimenez L; Heflin R; Quiel L
    Am J Ther; 2018; 25(6):e705-e706. PubMed ID: 29324464
    [No Abstract]   [Full Text] [Related]  

  • 2. Life Threatening Angioedema Due to Valsartan/Sacubitril With Previously Well-Tolerated ACE Inhibitor.
    Raheja H; Kumar V; Kamholz S; Hollander G; Shani J
    Am J Ther; 2018; 25(4):e508-e509. PubMed ID: 28452844
    [No Abstract]   [Full Text] [Related]  

  • 3. Angioedema Spotlight: A Closer Examination of Sacubitril/Valsartan Safety Results.
    Owens RE; Oliphant CS
    J Am Board Fam Med; 2017; 30(4):556-557. PubMed ID: 28720639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
    Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
    N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study.
    Shi V; Senni M; Streefkerk H; Modgill V; Zhou W; Kaplan A
    Int J Cardiol; 2018 Aug; 264():118-123. PubMed ID: 29776559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Prevalence of Adverse Events After Initiating Sacubitril/Valsartan Compared With Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Systolic Heart Failure.
    Adie S; Bitar A; Hanigan S; Pogue K; Koelling T; Dorsch M
    J Card Fail; 2019 May; 25(5):412-413. PubMed ID: 30904558
    [No Abstract]   [Full Text] [Related]  

  • 7. Sacubitril-valsartan: novel therapy for heart failure.
    Sehn E; McDonald T; Lindblad AJ
    Can Fam Physician; 2017 Sep; 63(9):697. PubMed ID: 28904036
    [No Abstract]   [Full Text] [Related]  

  • 8. Sacubitril + valsartan (Entresto°) in chronic heart failure.
    Prescrire Int; 2017 Feb; 26(179):33-37. PubMed ID: 30726626
    [No Abstract]   [Full Text] [Related]  

  • 9. Three cases of psychosis after use of sacubitril/valsartan.
    Pérez-Roselló V; Batalla-Monedero M; Sánchez-Lázaro I; López-Vilella R; Sierra-San Miguel P; Almenar-Bonet L
    Rev Esp Cardiol (Engl Ed); 2021 Jan; 74(1):103-105. PubMed ID: 32739142
    [No Abstract]   [Full Text] [Related]  

  • 10. Angioedema with sacubitril/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date.
    Dani SS; Ganatra S; Vaduganathan M
    Int J Cardiol; 2021 Jan; 323():188-191. PubMed ID: 32841619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of sacubitril/valsartan initiated during hospitalization: data from a non-selected cohort.
    López-Azor JC; Vicent L; Valero-Masa MJ; Esteban-Fernández A; Gómez-Bueno M; Pérez Á; Díez-Villanueva P; De-Juan J; Manuel-Iniesta Á; Bover R; Del Prado S; Martínez-Sellés M
    ESC Heart Fail; 2019 Dec; 6(6):1161-1166. PubMed ID: 31701680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety of sacubitril-valsartan for the treatment of chronic heart failure.
    Tyler JM; Teerlink JR
    Expert Opin Drug Saf; 2017 Feb; 16(2):257-263. PubMed ID: 28060547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure.
    Rodgers JE
    Am J Med; 2017 Jun; 130(6):635-639. PubMed ID: 28285069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sacubitril/Valsartan and Rhabdomyolysis: Reanalysis of a Potential Safety Signal.
    Woods RH
    Am J Cardiol; 2022 Jun; 173():145-146. PubMed ID: 35430084
    [No Abstract]   [Full Text] [Related]  

  • 15. Sacubitril/Valsartan (Entresto®)-Induced Hyponatremia.
    Fuzaylova I; Lam C; Talreja O; Makaryus AN; Ahern D; Cassagnol M
    J Pharm Pract; 2020 Oct; 33(5):696-699. PubMed ID: 30776953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What will be the impact of sacubitril/valsartan in clinical practice?
    Metra M
    J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e88-e90. PubMed ID: 29084021
    [No Abstract]   [Full Text] [Related]  

  • 17. Strength in synergy: Cardiometabolic effects of sacubitril/valsartan in heart failure and diabetes.
    Seferović PM; Polovina M; Seferović J; Rosano G
    Int J Cardiol; 2023 Jan; 371():293-294. PubMed ID: 36115444
    [No Abstract]   [Full Text] [Related]  

  • 18. Three case reports of involuntary muscular movements as adverse reactions to sacubitril/valsartan.
    Bejan-Angoulvant T; Genet T; Vrignaud L; Angoulvant D; Fauchier L
    Br J Clin Pharmacol; 2018 May; 84(5):1072-1074. PubMed ID: 29512176
    [No Abstract]   [Full Text] [Related]  

  • 19. Sacubitril/Valsartan (Entresto) for Heart Failure.
    Cheng J
    Am Fam Physician; 2016 Oct; 94(8):611-612. PubMed ID: 27929235
    [No Abstract]   [Full Text] [Related]  

  • 20. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.